Response to three years of growth hormone therapy in girls with Turner syndrome
PurposeShort stature is the most common finding in patients with Turner syndrome. Improving the final adult height in these patients is a challenge both for the patients and physicians. We investigated the clinical response of patients to growth hormone treatment for height improvement over the peri...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Korean Society of Pediatric Endocrinology
2013-03-01
|
Series: | Annals of Pediatric Endocrinology & Metabolism |
Subjects: | |
Online Access: | http://e-apem.org/upload/pdf/apem-18-13.pdf |
id |
doaj-2d9b50dd4e304387b52394058ece8917 |
---|---|
record_format |
Article |
spelling |
doaj-2d9b50dd4e304387b52394058ece89172020-11-24T22:28:05ZengKorean Society of Pediatric EndocrinologyAnnals of Pediatric Endocrinology & Metabolism2287-10122287-12922013-03-01181131810.6065/apem.2013.18.1.13499Response to three years of growth hormone therapy in girls with Turner syndromeHong Kyu Park0Hae Sang Lee1Jung Hee Ko2Il Tae Hwang3Jin Soon Hwang4Department of Pediatrics, Hallym University College of Medicine, Seoul, Korea.Department of Pediatrics, Ajou University School of Medicine, Suwon, Korea.Department of Pediatrics, Ajou University School of Medicine, Suwon, Korea.Department of Pediatrics, Hallym University College of Medicine, Seoul, Korea.Department of Pediatrics, Ajou University School of Medicine, Suwon, Korea.PurposeShort stature is the most common finding in patients with Turner syndrome. Improving the final adult height in these patients is a challenge both for the patients and physicians. We investigated the clinical response of patients to growth hormone treatment for height improvement over the period of three years.MethodsReview of medical records from 27 patients with Turner syndrome treated with recombinant human growth hormone for more than 3 years was done. Differences in the changes of height standard deviation scores according to karyotype were measured and factors influencing the height changes were analyzed.ResultsThe response to recombinant human growth hormone was an increase in the height of the subjects to a mean value of 1.1 standard deviation for subjects with Turner syndrome at the end of the 3-year treatment. The height increment in the first year was highest. The height standard deviation score in the third year was negatively correlated with the age at the beginning of the recombinant human growth hormone treatment. Different karyotypes in subjects did not seem to affect the height changes.ConclusionEarly growth hormone administration in subjects with Turner syndrome is helpful to improve height response to the treatment.http://e-apem.org/upload/pdf/apem-18-13.pdfTurner syndromeGrowth hormoneTreatment outcome |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Hong Kyu Park Hae Sang Lee Jung Hee Ko Il Tae Hwang Jin Soon Hwang |
spellingShingle |
Hong Kyu Park Hae Sang Lee Jung Hee Ko Il Tae Hwang Jin Soon Hwang Response to three years of growth hormone therapy in girls with Turner syndrome Annals of Pediatric Endocrinology & Metabolism Turner syndrome Growth hormone Treatment outcome |
author_facet |
Hong Kyu Park Hae Sang Lee Jung Hee Ko Il Tae Hwang Jin Soon Hwang |
author_sort |
Hong Kyu Park |
title |
Response to three years of growth hormone therapy in girls with Turner syndrome |
title_short |
Response to three years of growth hormone therapy in girls with Turner syndrome |
title_full |
Response to three years of growth hormone therapy in girls with Turner syndrome |
title_fullStr |
Response to three years of growth hormone therapy in girls with Turner syndrome |
title_full_unstemmed |
Response to three years of growth hormone therapy in girls with Turner syndrome |
title_sort |
response to three years of growth hormone therapy in girls with turner syndrome |
publisher |
Korean Society of Pediatric Endocrinology |
series |
Annals of Pediatric Endocrinology & Metabolism |
issn |
2287-1012 2287-1292 |
publishDate |
2013-03-01 |
description |
PurposeShort stature is the most common finding in patients with Turner syndrome. Improving the final adult height in these patients is a challenge both for the patients and physicians. We investigated the clinical response of patients to growth hormone treatment for height improvement over the period of three years.MethodsReview of medical records from 27 patients with Turner syndrome treated with recombinant human growth hormone for more than 3 years was done. Differences in the changes of height standard deviation scores according to karyotype were measured and factors influencing the height changes were analyzed.ResultsThe response to recombinant human growth hormone was an increase in the height of the subjects to a mean value of 1.1 standard deviation for subjects with Turner syndrome at the end of the 3-year treatment. The height increment in the first year was highest. The height standard deviation score in the third year was negatively correlated with the age at the beginning of the recombinant human growth hormone treatment. Different karyotypes in subjects did not seem to affect the height changes.ConclusionEarly growth hormone administration in subjects with Turner syndrome is helpful to improve height response to the treatment. |
topic |
Turner syndrome Growth hormone Treatment outcome |
url |
http://e-apem.org/upload/pdf/apem-18-13.pdf |
work_keys_str_mv |
AT hongkyupark responsetothreeyearsofgrowthhormonetherapyingirlswithturnersyndrome AT haesanglee responsetothreeyearsofgrowthhormonetherapyingirlswithturnersyndrome AT jungheeko responsetothreeyearsofgrowthhormonetherapyingirlswithturnersyndrome AT iltaehwang responsetothreeyearsofgrowthhormonetherapyingirlswithturnersyndrome AT jinsoonhwang responsetothreeyearsofgrowthhormonetherapyingirlswithturnersyndrome |
_version_ |
1725747912818819072 |